Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 2
1993 2
1996 1
1997 3
2004 2
2005 2
2006 2
2007 4
2008 3
2009 6
2010 9
2011 10
2012 16
2013 8
2014 9
2015 7
2016 3
2018 5
2019 13
2020 12
2021 14
2022 18
2023 12
2024 14
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

165 results

Results by year

Filters applied: . Clear all
Page 1
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.
Ryan P, Blanco JL, Masia M, Garcia-Fraile L, Crusells MJ, Domingo P, Curran A, Guerri-Fernandez R, Bernal E, Bravo J, Revollo B, Macias J, Tiraboschi JM, Montejano R, Amador C, Torralba M, Merino D, Diaz-Brito V, Galindo MJ, Ferra S, Villoslada A, Losa JE, Fanjul FJ, Perez-Stachowski X, Peraire J, Portilla J, de la Fuente S, Dueñas C, Vazquez MJ, Di Gregorio S, Esteban H, Gil P, de Miguel M, Alejos B, Martínez E; PASO-DOBLE study group. Ryan P, et al. Among authors: peraire j. Lancet HIV. 2025 Jul;12(7):e473-e484. doi: 10.1016/S2352-3018(25)00105-5. Epub 2025 Jun 7. Lancet HIV. 2025. PMID: 40489982 Clinical Trial.
The HIV-1 reservoir landscape in persistent elite controllers and transient elite controllers.
Gasca-Capote C, Lian X, Gao C, Roseto IC, Jiménez-León MR, Gladkov G, Camacho-Sojo MI, Pérez-Gómez A, Gallego I, Lopez-Cortes LE, Bachiller S, Vitalle J, Rafii-El-Idrissi Benhnia M, Ostos FJ, Collado-Romacho AR, Santos J, Palacios R, Gomez-Ayerbe C, Muñoz-Medina L, Ruiz-Sancho A, Frias M, Rivero-Juarez A, Roca-Oporto C, Hidalgo-Tenorio C, Rull A, Olalla J, Lopez-Ruz MA, Vidal F, Viladés C, Mastrangelo A, Cavassini M, Espinosa N, Perreau M, Peraire J, Rivero A, López-Cortes LF, Lichterfeld M, Yu XG, Ruiz-Mateos E. Gasca-Capote C, et al. Among authors: peraire j. J Clin Invest. 2024 Feb 20;134(8):e174215. doi: 10.1172/JCI174215. J Clin Invest. 2024. PMID: 38376918 Free PMC article.
Mitochondrial Haplogroups and Weight Gain After Initiating ART in Patients With HIV.
Berenguer J, Jarrín I, Bellón JM, Díez C, Jiménez-Sousa MA, López JC, Pinto-Martínez A, Moreno S, Montes ML, Iribarren JA, Orviz E, Portilla J, Villarroya F, Domingo P, Resino S; CoRIS Cohort. Berenguer J, et al. J Infect Dis. 2024 Aug 16;230(2):421-425. doi: 10.1093/infdis/jiae168. J Infect Dis. 2024. PMID: 38557859
Rat hepatitis E virus (Rocahepevirus ratti) in people living with HIV.
Casares-Jimenez M, Rivero-Juarez A, Lopez-Lopez P, Montes ML, Navarro-Soler R, Peraire J, Espinosa N, Alemán-Valls MR, Garcia-Garcia T, Caballero-Gomez J, Corona-Mata D, Perez-Valero I, Ulrich RG, Rivero A. Casares-Jimenez M, et al. Among authors: peraire j. Emerg Microbes Infect. 2024 Dec;13(1):2295389. doi: 10.1080/22221751.2023.2295389. Epub 2023 Dec 30. Emerg Microbes Infect. 2024. PMID: 38095070 Free PMC article.
Multi-omics in HIV: searching insights to understand immunological non-response in PLHIV.
Espineira S, Flores-Piñas M, Chafino S, Viladés C, Negredo E, Fernández-Arroyo S, Mallolas J, Villar B, Moreno S, Vidal F, Rull A, Peraire J. Espineira S, et al. Among authors: peraire j. Front Immunol. 2023 Aug 15;14:1228795. doi: 10.3389/fimmu.2023.1228795. eCollection 2023. Front Immunol. 2023. PMID: 37649488 Free PMC article. Review.
Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain.
Izquierdo R, Suárez-García I, Gómez-García T, Marco-Sánchez C, Puente-Ferreiro J, Moreno C, Diaz A, Cabello-Clotet N, Vinuesa D, Blanco JL, Melús E, Gómez-Ayerbe C, Olalla J, Riera M, Bernardino JI, de López Bernaldo de Quirós JC, Moreno S, Jarrín I; CoRIS cohort. Izquierdo R, et al. HIV Med. 2025 Feb;26(2):308-318. doi: 10.1111/hiv.13726. Epub 2024 Oct 25. HIV Med. 2025. PMID: 39455423 Free PMC article.
Impact of the initial administration of an antiretroviral drug with latency reversal properties on the HIV reservoir size.
De La Torre Tarazona E, Moraga E, Vaquer R, Sánchez-Palomino S, de Lazzari E, Luna L, Vicens-Artés S, García Fraile LJ, Peraire J, Garcia-Gasalla M, Balsalobre L, Guillén Martínez S, López Cortés LF, Jarrín I, Serrano-Villar S, Alcamí J, Moreno S; CoRIS Cohort. De La Torre Tarazona E, et al. Among authors: peraire j. Sci Rep. 2025 Jul 13;15(1):25306. doi: 10.1038/s41598-025-09474-1. Sci Rep. 2025. PMID: 40653494 Free PMC article.
Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: an analysis of a multicentre cohort at 96 weeks.
Suárez-García I, Alejos B, Moreno C, Martín Torres J, Masiá M, García-Fraile LJ, Riera M, Dalmau D, Rodríguez-Rosado R, Muga R, Moreno S, Jarrín I; CoRIS cohort. Suárez-García I, et al. J Antimicrob Chemother. 2025 Mar 3;80(3):682-691. doi: 10.1093/jac/dkae456. J Antimicrob Chemother. 2025. PMID: 39710424 Free PMC article.
Health-related quality of life in people with HIV from the multicentre CoRIS cohort in Spain: Associated factors and short-term changes over time.
Izquierdo R, Suárez-García I, Marco-Sánchez C, Pérez-Latorre L, Riera M, Cano J, Viladés C, Reus S, Olalla J, González-Ruano P, Orviz E, Díaz A, Moreno S, Jarrín I; CoRIS cohort. Izquierdo R, et al. HIV Med. 2025 Apr;26(4):606-620. doi: 10.1111/hiv.13762. Epub 2025 Jan 21. HIV Med. 2025. PMID: 39835516 Free PMC article.
165 results